NEOTHYLLINE
LOE ApproachingNDAORALELIXIR
Approved
Mar 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEOTHYLLINE is an oral elixir approved in 1951 as an NDA product under Teva sponsorship. The generic name and mechanism of action are not publicly disclosed in available data. Patient populations and therapeutic indications require further clinical documentation.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting a team focused on lifecycle management and generic mitigation rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEOTHYLLINE shows zero linked job openings, reflecting its mature, low-growth status within Teva's portfolio. Career roles are primarily defensive, focused on regulatory compliance, cost optimization, and managed decline rather than innovation or expansion.
Brand Manager (Legacy)Regulatory Affairs Specialist
Worked on NEOTHYLLINE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.